We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Arcturus Therapeutics and Catalent have announced a partnership to manufacture mRNA-based COVID-19 vaccine candidate, intended to protect against the SARS-CoV-2 coronavirus.
